Frontiers3d
NAFLD treatment in diabetes: from current dietary interventions to novel treatment
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
Medindia14d
Asah1 Gene Identified as Potential Target for Treating Liver Disease
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...
Fox News14d
Lingering lung disorders 5 years post-COVID: Here's what to know
The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...
Taiwan News15d
The Global Liver Fibrosis Treatment Market: Growth Trends and Opportunities
The primary causes of liver fibrosis include alcohol abuse, chronic hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Despite ...
Armed robbery in Revesby15d
Researchers Identify Gene To Guide Novel Therapeutics Of Nonalcoholic Fatty Liver Diseases
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...
Investing16d
Lantheus at TD Cowen Conference: Strategic Growth in Radiopharmaceuticals
cardiac fibrosis, NASH or NASH, you know, there’s no end to potential applications here. And I think the challenge that we have as a company is to figure out the right path forward, the right non ...
Science Daily17d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...